{"url_path":"/sec/ikt/8-k/2026-08-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1750149/0001193125-26-344623-index.html","accession_number":"0001193125-26-344623","cik":"0001750149","ticker":"IKT","issuer_name":"Inhibikase Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1750149/0001193125-26-344623-index.html","primary_entity_key":"0001750149","primary_entity_name":"Inhibikase Therapeutics, Inc."},"word_count":81,"has_tables":true,"body_markdown":"Item 9.01.\n\nFinancial Statements and Exhibits.\n\n \n\n(d)\n\nExhibits.\n\n \n\n99.1\n\n[Press Release issued by Inhibikase Therapeutics, Inc., dated August 11, 2026, furnished herewith.](d134059dex991.htm)\n\n \n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDate: August 11, 2026\n \nINHIBIKASE THERAPEUTICS, INC.\n\n \n\n \nBy:\n \n\n/s/ Mark Iwicki\n\n \n\n \n\n \nMark Iwicki\n\n \n\n \n\n \nChief Executive Officer"}